Information Technology Services
Compare Stocks
5 / 10Stock Comparison
NOTE vs SPGI vs ICE vs MSCI vs CME
Revenue, margins, valuation, and 5-year total return — side by side.
Financial - Data & Stock Exchanges
Financial - Data & Stock Exchanges
Financial - Data & Stock Exchanges
Financial - Data & Stock Exchanges
NOTE vs SPGI vs ICE vs MSCI vs CME — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Information Technology Services | Financial - Data & Stock Exchanges | Financial - Data & Stock Exchanges | Financial - Data & Stock Exchanges | Financial - Data & Stock Exchanges |
| Market Cap | $3M | $126.89B | $88.45B | $42.83B | $104.07B |
| Revenue (TTM) | $88M | $15.34B | $12.64B | $3.13B | $6.52B |
| Net Income (TTM) | $-105M | $4.78B | $3.30B | $1.32B | $4.24B |
| Gross Margin | 69.9% | 70.2% | 61.9% | 82.4% | 86.1% |
| Operating Margin | -74.9% | 42.2% | 38.7% | 54.7% | 64.9% |
| Forward P/E | — | 21.8x | 19.5x | 30.0x | 23.5x |
| Total Debt | $173M | $14.20B | $20.28B | $6.31B | $3.76B |
| Cash & Equiv. | $29M | $1.75B | $837M | $515M | $4.42B |
NOTE vs SPGI vs ICE vs MSCI vs CME — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| FiscalNote Holdings… (NOTE) | 100 | 0.2 | -99.8% |
| S&P Global Inc. (SPGI) | 100 | 130.4 | +30.4% |
| Intercontinental Ex… (ICE) | 100 | 135.4 | +35.4% |
| MSCI Inc. (MSCI) | 100 | 131.8 | +31.8% |
| CME Group Inc. (CME) | 100 | 157.6 | +57.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NOTE vs SPGI vs ICE vs MSCI vs CME
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NOTE lags the leaders in this set but could rank higher in a more targeted comparison.
SPGI is the clearest fit if your priority is growth exposure.
- Rev growth 7.9%, EPS growth 18.7%
ICE is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 14 yrs, beta 0.33, yield 1.2%
- Lower volatility, beta 0.33, Low D/E 69.9%, current ratio 1.02x
- Beta 0.33, yield 1.2%, current ratio 1.02x
- Lower P/E (19.5x vs 30.0x)
MSCI carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 7.2% 10Y total return vs CME's 284.9%
- 9.7% NII/revenue growth vs NOTE's -20.7%
- +7.8% vs NOTE's -97.4%
- 24.0% ROA vs NOTE's -40.6%, ROIC 34.9% vs -0.1%
CME ranks third and is worth considering specifically for valuation efficiency.
- PEG 1.71 vs SPGI's 2.51
- 62.0% margin vs NOTE's -119.0%
- 3.8% yield, 6-year raise streak, vs ICE's 1.2%, (1 stock pays no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.7% NII/revenue growth vs NOTE's -20.7% | |
| Value | Lower P/E (19.5x vs 30.0x) | |
| Quality / Margins | 62.0% margin vs NOTE's -119.0% | |
| Stability / Safety | Beta 0.33 vs NOTE's 2.79 | |
| Dividends | 3.8% yield, 6-year raise streak, vs ICE's 1.2%, (1 stock pays no dividend) | |
| Momentum (1Y) | +7.8% vs NOTE's -97.4% | |
| Efficiency (ROA) | 24.0% ROA vs NOTE's -40.6%, ROIC 34.9% vs -0.1% |
NOTE vs SPGI vs ICE vs MSCI vs CME — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NOTE vs SPGI vs ICE vs MSCI vs CME — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CME leads in 2 of 6 categories
NOTE leads 0 • SPGI leads 0 • ICE leads 0 • MSCI leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CME leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
SPGI is the larger business by revenue, generating $15.3B annually — 174.4x NOTE's $88M. CME is the more profitable business, keeping 62.0% of every revenue dollar as net income compared to NOTE's -119.0%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $88M | $15.3B | $12.6B | $3.1B | $6.5B |
| EBITDAEarnings before interest/tax | -$54M | $7.8B | $6.5B | $2.0B | $4.7B |
| Net IncomeAfter-tax profit | -$105M | $4.8B | $3.3B | $1.3B | $4.2B |
| Free Cash FlowCash after capex | -$19M | $5.6B | $4.3B | $1.5B | $4.4B |
| Gross MarginGross profit ÷ Revenue | +69.9% | +70.2% | +61.9% | +82.4% | +86.1% |
| Operating MarginEBIT ÷ Revenue | -74.9% | +42.2% | +38.7% | +54.7% | +64.9% |
| Net MarginNet income ÷ Revenue | -119.0% | +29.2% | +26.1% | +38.4% | +62.0% |
| FCF MarginFCF ÷ Revenue | -21.2% | +35.6% | +33.9% | +49.4% | +64.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -27.2% | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -6.0% | +32.5% | +23.1% | +49.1% | +21.4% |
Valuation Metrics
Evenly matched — NOTE and ICE each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 25.7x trailing earnings, CME trades at a 32% valuation discount to MSCI's 37.8x P/E. Adjusting for growth (PEG ratio), CME offers better value at 1.87x vs SPGI's 3.36x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3M | $126.9B | $88.4B | $42.8B | $104.1B |
| Enterprise ValueMkt cap + debt − cash | $147M | $139.3B | $107.9B | $48.6B | $103.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.04x | 29.24x | 27.06x | 37.81x | 25.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 21.84x | 19.48x | 29.99x | 23.49x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.36x | 3.05x | 2.23x | 1.87x |
| EV / EBITDAEnterprise value multiple | — | 18.20x | 16.71x | 25.17x | 22.96x |
| Price / SalesMarket cap ÷ Revenue | 0.03x | 8.27x | 7.00x | 13.67x | 15.96x |
| Price / BookPrice ÷ Book value/share | 0.00x | 3.62x | 3.08x | — | 3.60x |
| Price / FCFMarket cap ÷ FCF | — | 23.26x | 20.62x | 27.65x | 24.82x |
Profitability & Efficiency
Evenly matched — MSCI and CME each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
CME delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-161 for NOTE. NOTE carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ICE's 0.70x. On the Piotroski fundamental quality scale (0–9), ICE scores 9/9 vs NOTE's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -160.9% | +12.9% | +11.6% | — | +15.3% |
| ROA (TTM)Return on assets | -40.6% | +7.9% | +2.3% | +24.0% | +2.2% |
| ROICReturn on invested capital | -0.1% | +9.7% | +7.5% | +34.9% | +10.2% |
| ROCEReturn on capital employed | -0.0% | +12.1% | +9.5% | +44.3% | +3.6% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 9 | 8 | 5 |
| Debt / EquityFinancial leverage | 0.00x | 0.39x | 0.70x | — | 0.13x |
| Net DebtTotal debt minus cash | $144M | $12.5B | $19.4B | $5.8B | -$666M |
| Cash & Equiv.Liquid assets | $29M | $1.7B | $837M | $515M | $4.4B |
| Total DebtShort + long-term debt | $173M | $14.2B | $20.3B | $6.3B | $3.8B |
| Interest CoverageEBIT ÷ Interest expense | -2.58x | 22.69x | 6.53x | 7.67x | 41.55x |
Total Returns (Dividends Reinvested)
CME leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CME five years ago would be worth $16,450 today (with dividends reinvested), compared to $17 for NOTE. Over the past 12 months, MSCI leads with a +7.8% total return vs NOTE's -97.4%. The 3-year compound annual growth rate (CAGR) favors CME at 19.7% vs NOTE's -78.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -87.4% | -16.2% | -2.1% | +4.5% | +9.1% |
| 1-Year ReturnPast 12 months | -97.4% | -14.5% | -10.4% | +7.8% | +4.6% |
| 3-Year ReturnCumulative with dividends | -99.0% | +23.8% | +50.8% | +28.6% | +71.4% |
| 5-Year ReturnCumulative with dividends | -99.8% | +14.2% | +43.4% | +27.9% | +64.5% |
| 10-Year ReturnCumulative with dividends | -99.8% | +337.1% | +225.3% | +720.9% | +284.9% |
| CAGR (3Y)Annualised 3-year return | -78.4% | +7.4% | +14.7% | +8.7% | +19.7% |
Risk & Volatility
Evenly matched — MSCI and CME each lead in 1 of 2 comparable metrics.
Risk & Volatility
CME is the less volatile stock with a -0.30 beta — it tends to amplify market swings less than NOTE's 2.79 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MSCI currently trades 93.9% from its 52-week high vs NOTE's 2.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.79x | 0.58x | 0.33x | 0.61x | -0.30x |
| 52-Week HighHighest price in past year | $10.20 | $579.05 | $189.35 | $626.28 | $329.16 |
| 52-Week LowLowest price in past year | $0.15 | $381.61 | $143.17 | $501.08 | $257.17 |
| % of 52W HighCurrent price vs 52-week peak | +2.0% | +74.0% | +82.5% | +93.9% | +87.1% |
| RSI (14)Momentum oscillator 0–100 | 28.7 | 42.4 | 38.8 | 54.6 | 44.1 |
| Avg Volume (50D)Average daily shares traded | 492K | 1.8M | 3.0M | 520K | 2.2M |
Analyst Outlook
Evenly matched — ICE and CME each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SPGI as "Buy", ICE as "Buy", MSCI as "Buy", CME as "Hold". Consensus price targets imply 27.9% upside for SPGI (target: $548) vs 11.6% for CME (target: $320). For income investors, CME offers the higher dividend yield at 3.81% vs SPGI's 0.89%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $548.11 | $195.71 | $674.33 | $320.25 |
| # AnalystsCovering analysts | — | 28 | 36 | 27 | 35 |
| Dividend YieldAnnual dividend ÷ price | — | +0.9% | +1.2% | +1.2% | +3.8% |
| Dividend StreakConsecutive years of raises | — | 12 | 14 | 11 | 6 |
| Dividend / ShareAnnual DPS | — | $3.83 | $1.93 | $7.20 | $10.92 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.9% | +1.6% | +5.8% | +0.3% |
CME leads in 2 of 6 categories — strongest in Income & Cash Flow and Total Returns. 4 categories are tied.
NOTE vs SPGI vs ICE vs MSCI vs CME: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NOTE or SPGI or ICE or MSCI or CME a better buy right now?
For growth investors, MSCI Inc.
(MSCI) is the stronger pick with 9. 7% revenue growth year-over-year, versus -20. 7% for FiscalNote Holdings, Inc. (NOTE). CME Group Inc. (CME) offers the better valuation at 25. 7x trailing P/E (23. 5x forward), making it the more compelling value choice. Analysts rate S&P Global Inc. (SPGI) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NOTE or SPGI or ICE or MSCI or CME?
On trailing P/E, CME Group Inc.
(CME) is the cheapest at 25. 7x versus MSCI Inc. at 37. 8x. On forward P/E, Intercontinental Exchange, Inc. is actually cheaper at 19. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CME Group Inc. wins at 1. 71x versus S&P Global Inc. 's 2. 51x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — NOTE or SPGI or ICE or MSCI or CME?
Over the past 5 years, CME Group Inc.
(CME) delivered a total return of +64. 5%, compared to -99. 8% for FiscalNote Holdings, Inc. (NOTE). Over 10 years, the gap is even starker: MSCI returned +720. 9% versus NOTE's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NOTE or SPGI or ICE or MSCI or CME?
By beta (market sensitivity over 5 years), CME Group Inc.
(CME) is the lower-risk stock at -0. 30β versus FiscalNote Holdings, Inc. 's 2. 79β — meaning NOTE is approximately -1016% more volatile than CME relative to the S&P 500. On balance sheet safety, FiscalNote Holdings, Inc. (NOTE) carries a lower debt/equity ratio of 0% versus 70% for Intercontinental Exchange, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NOTE or SPGI or ICE or MSCI or CME?
By revenue growth (latest reported year), MSCI Inc.
(MSCI) is pulling ahead at 9. 7% versus -20. 7% for FiscalNote Holdings, Inc. (NOTE). On earnings-per-share growth, the picture is similar: Intercontinental Exchange, Inc. grew EPS 20. 7% year-over-year, compared to -660. 2% for FiscalNote Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NOTE or SPGI or ICE or MSCI or CME?
CME Group Inc.
(CME) is the more profitable company, earning 62. 0% net margin versus -68. 4% for FiscalNote Holdings, Inc. — meaning it keeps 62. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CME leads at 64. 9% versus -38. 9% for NOTE. At the gross margin level — before operating expenses — CME leads at 86. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NOTE or SPGI or ICE or MSCI or CME more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, CME Group Inc. (CME) is the more undervalued stock at a PEG of 1. 71x versus S&P Global Inc. 's 2. 51x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Intercontinental Exchange, Inc. (ICE) trades at 19. 5x forward P/E versus 30. 0x for MSCI Inc. — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SPGI: 27. 9% to $548. 11.
08Which pays a better dividend — NOTE or SPGI or ICE or MSCI or CME?
In this comparison, CME (3.
8% yield), ICE (1. 2% yield), MSCI (1. 2% yield), SPGI (0. 9% yield) pay a dividend. NOTE does not pay a meaningful dividend and should not be held primarily for income.
09Is NOTE or SPGI or ICE or MSCI or CME better for a retirement portfolio?
For long-horizon retirement investors, CME Group Inc.
(CME) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 30), 3. 8% yield, +284. 9% 10Y return). FiscalNote Holdings, Inc. (NOTE) carries a higher beta of 2. 79 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CME: +284. 9%, NOTE: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NOTE and SPGI and ICE and MSCI and CME?
These companies operate in different sectors (NOTE (Technology) and SPGI (Financial Services) and ICE (Financial Services) and MSCI (Financial Services) and CME (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NOTE is a small-cap quality compounder stock; SPGI is a mid-cap quality compounder stock; ICE is a mid-cap quality compounder stock; MSCI is a mid-cap quality compounder stock; CME is a mid-cap income-oriented stock. SPGI, ICE, MSCI, CME pay a dividend while NOTE does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.